0001104659-21-007942.txt : 20210127 0001104659-21-007942.hdr.sgml : 20210127 20210127074128 ACCESSION NUMBER: 0001104659-21-007942 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210127 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210127 DATE AS OF CHANGE: 20210127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 21556738 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm214153d1_8k.htm FORM 8-K
0000001800 false Common Shares, Without Par Value ABT 0000001800 2021-01-27 2021-01-27 0000001800 us-gaap:CommonStockMember exch:XCHI 2021-01-27 2021-01-27 0000001800 us-gaap:CommonStockMember exch:XNYS 2021-01-27 2021-01-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

January 27, 2021

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading
Symbol(s)		 Name of Each Exchange
on Which Registered
Common Shares, Without Par Value ABT New York Stock Exchange
Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 2.02Results of Operations and Financial Condition

 

On January 27, 2021, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2020.

 

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.  In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items.  These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions and restructuring actions, charges related to cost reduction initiatives, the acquisition of R&D assets, charges related to impairment of certain assets, income related to certain litigation settlements, and tax benefits associated with specified items, tax benefits associated with the resolution of various tax positions related to prior years and excess tax benefits associated with share-based compensation.  These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance.  Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance.  Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses.  Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.  

 

Item 9.01Financial Statements and Exhibits

 

  Exhibit No.  Exhibit

 

99.1Press Release dated January 27, 2021 (furnished pursuant to Item 2.02).

 

104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES

 

Date: January 27, 2021 By: /s/ Robert E. Funck, Jr.
    Robert E. Funck, Jr.
    Executive Vice President, Finance and Chief Financial Officer

 

 

 

 EX-99.1 2 tm214153d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

News Release

 

 

Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021

 

-Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales

-Sales growth of 28.7 percent; organic sales growth of 28.4 percent

-GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent

-Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020

-R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas

-Issues 2021 EPS growth forecast of more than 35 percent

 
 

ABBOTT PARK, Ill., Jan. 27, 2021 — Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for 2021.

·Fourth-quarter sales of $10.7 billion increased 28.7 percent on a reported basis and 28.4 percent on an organic basis, which excludes the impact of foreign exchange.

·Fourth-quarter GAAP diluted EPS was $1.20 and adjusted diluted EPS, which excludes specified items, was $1.45, reflecting 52.6 percent growth versus the prior year.1

·Full-year 2020 GAAP diluted EPS from continuing operations was $2.49 and adjusted diluted EPS from continuing operations was $3.65, at the upper-end of guidance range issued in January 2020.2

·Abbott issues full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.74 and full-year adjusted diluted EPS from continuing operations of at least $5.00, reflecting growth of more than 35 percent versus the prior year.3

·In the fourth quarter, global COVID-19 testing-related sales were $2.4 billion, led by combined sales of $1.9 billion from Abbott's BinaxNOW™, Panbio™ and ID NOW™ rapid testing platforms.

·R&D pipeline continued to be highly productive in 2020: U.S. approval of FreeStyle® Libre 2 and CE Mark of FreeStyle Libre 3 and Libre Sense Glucose Sport Biosensor; CE Mark of MitraClip® G4, TriClip™ and Tendyne™ heart valve devices; U.S. approval of Gallant™ cardiac rhythm devices; CE Mark of EnSite™ X 3D cardiac mapping system; portfolio expansions in Nutrition and Established Pharmaceuticals.

 

"Despite challenging conditions, we achieved double-digit EPS growth, delivered ground-breaking innovation and advanced our new product pipeline in 2020," said Robert B. Ford, president and chief executive officer, Abbott. "We exited the year with a lot of momentum and are forecasting EPS growth of more than 35 percent in 2021."

 

—more—

 

 

 

Fourth-Quarter Business Overview

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

 

Following are sales by business segment and commentary for the fourth quarter 2020:

 

Total Company

($ in millions)

 

               % Change vs. 4Q19 
   Sales 4Q20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total *   4,199    6,502    10,701    41.8    21.4    28.7    41.8    20.9    28.4 
Nutrition   841    1,095    1,936    6.5    1.4    3.6    6.5    2.9    4.4 
Diagnostics   1,981    2,364    4,345    158.5    83.0    111.1    158.5    79.6    108.9 
Established Pharmaceuticals   --    1,147    1,147     n/a     (2.3)   (2.3)    n/a     3.4    3.4 
Medical Devices   1,369    1,888    3,257    (2.5)   4.9    1.7    (2.5)   1.2    (0.4)

 

* Total Q4 2020 Abbott sales from continuing operations include Other Sales of approximately $16 million.

 

               % Change vs. 12M19 
   Sales 12M20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total *   13,022    21,586    34,608    14.2    5.3    8.5    14.2    7.3    9.8 
Nutrition   3,279    4,368    7,647    5.4    1.6    3.2    5.4    4.2    4.7 
Diagnostics   4,774    6,031    10,805    65.3    25.0    40.1    65.3    25.8    40.6 
Established Pharmaceuticals   --    4,303    4,303     n/a     (4.1)   (4.1)    n/a     1.9    1.9 
Medical Devices   4,931    6,856    11,787    (8.2)   (0.1)   (3.7)   (8.2)   (0.3)   (3.8)

 

* Total 12M 2020 Abbott sales from continuing operations include Other Sales of approximately $66 million.

 

n/a = Not Applicable.

 

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

Fourth-quarter 2020 worldwide sales of $10.7 billion increased 28.7 percent on a reported basis and 28.4 percent on an organic basis.

 

2

 

 

Nutrition

($ in millions)

 

               % Change vs. 4Q19 
   Sales 4Q20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   841    1,095    1,936    6.5    1.4    3.6    6.5    2.9    4.4 
Pediatric   497    511    1,008    5.2    (9.5)   (2.8)   5.2    (8.4)   (2.2)
Adult   344    584    928    8.4    13.4    11.5    8.4    15.3    12.7 

 

               % Change vs. 12M19 
   Sales 12M20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   3,279    4,368    7,647    5.4    1.6    3.2    5.4    4.2    4.7 
Pediatric   1,987    2,140    4,127    5.8    (6.2)   (0.8)   5.8    (4.1)   0.3 
Adult   1,292    2,228    3,520    4.9    10.5    8.4    4.9    13.6    10.3 

 

Worldwide Nutrition sales increased 3.6 percent on a reported basis and 4.4 percent on an organic basis in the fourth quarter. Strong performance of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading diabetes nutrition brand, led to global Adult Nutrition sales growth of 11.5 percent on a reported basis and 12.7 percent on an organic basis. In Pediatric Nutrition, U.S. sales growth of 5.2 percent was led by share growth of Similac®, Abbott's infant formula brand, which was offset by challenging conditions in Greater China.

 

3

 

 

Diagnostics

($ in millions)

 

               % Change vs. 4Q19 
   Sales 4Q20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   1,981    2,364    4,345    158.5    83.0    111.1    158.5    79.6    108.9 
Core Laboratory   326    997    1,323    10.9    4.3    5.9    10.9    3.3    5.1 
Molecular   192    290    482    427.0    263.1    314.5    427.0    254.2    308.3 
Point of Care   91    38    129    (11.9)   14.2    (5.5)   (11.9)   12.3    (6.0)
Rapid Diagnostics   1,372    1,039    2,411    312.2    366.2    333.9    312.2    354.0    329.0 

 

               % Change vs. 12M19 
   Sales 12M20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   4,774    6,031    10,805    65.3    25.0    40.1    65.3    25.8    40.6 
Core Laboratory   1,166    3,309    4,475    7.3    (7.3)   (3.9)   7.3    (5.9)   (2.8)
Molecular   621    817    1,438    315.5    178.8    224.9    315.5    179.9    225.7 
Point of Care   369    147    516    (15.9)   20.2    (8.0)   (15.9)   20.6    (7.9)
Rapid Diagnostics   2,618    1,758    4,376    115.7    109.2    113.0    115.7    107.4    112.3 

 

Worldwide Diagnostics sales increased 111.1 percent on a reported basis in the fourth quarter and increased 108.9 percent on an organic basis. Strong growth in the quarter was driven by demand for Abbott's portfolio of COVID-19 diagnostics tests across its rapid and lab-based platforms. Global COVID-19 testing-related sales were $2.4 billion in the fourth quarter, led by combined sales of $1.9 billion from Abbott's BinaxNOW, Panbio and ID NOW rapid testing platforms.

 

During 2020, Abbott mobilized its teams across multiple fronts to develop and launch multiple diagnostic tests for COVID-19:

·U.S. Emergency Use Authorization (EUA) of BinaxNOW COVID-19 Ag Card test, a portable, lateral flow rapid antigen test to detect COVID-19.

·CE Mark and World Health Organization emergency use listing of Panbio rapid antigen test to detect COVID-19.

·U.S. EUA of molecular test to detect COVID-19 on its ID NOW rapid point-of-care platform.

·U.S. EUA and CE Mark of molecular test on its m2000™ RealTime lab-based platform to detect COVID-19.

·U.S. EUA and CE Mark of molecular test on its Alinity™ m system to detect COVID-19.

·U.S. EUA and CE Mark of IgG (Immunoglobulin G) lab-based serology blood test on its ARCHITECT® i1000SR and i2000SR laboratory instruments for the detection of an antibody to determine if someone was previously infected with the virus.

·U.S. EUA and CE Mark of SARS-CoV-2 IgG lab-based serology blood test on its Alinity i system.

·Lateral flow COVID-19 rapid antibody test on its Panbio system in select countries for the detection of an antibody to determine if someone was previously infected with the virus.

·U.S. EUA and CE Mark of AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test for use on its ARCHITECT and Alinity platforms.

·CE Mark of IgG (Immunoglobulin G) quantitative lab-based serology test for use on its ARCHITECT and Alinity platforms.

·CE Mark of multiplex molecular tests on its Alinity m system to detect COVID-19, Flu A/B and RSV.

 

4

 

 

Established Pharmaceuticals

($ in millions)

 

               % Change vs. 4Q19 
   Sales 4Q20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   --    1,147    1,147     n/a     (2.3)   (2.3)    n/a     3.4    3.4 
Key Emerging Markets   --    833    833     n/a     (7.1)   (7.1)    n/a     1.1    1.1 
Other   --    314    314     n/a     13.0    13.0     n/a     10.8    10.8 

 

               % Change vs. 12M19 
   Sales 12M20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   --    4,303    4,303     n/a     (4.1)   (4.1)    n/a     1.9    1.9 
Key Emerging Markets   --    3,209    3,209     n/a     (5.4)   (5.4)    n/a     2.6    2.6 
Other   --    1,094    1,094     n/a     -    -     n/a     (0.5)   (0.5)

 

Established Pharmaceuticals sales decreased 2.3 percent on a reported basis in the fourth quarter and increased 3.4 percent on an organic basis.

 

Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies decreased 7.1 percent on a reported basis in the quarter and increased 1.1 percent on an organic basis. Organic sales growth in India, Russia and Brazil was partially offset by market softness across several countries as a result of COVID-19.

 

Other sales increased 13.0 percent on a reported basis in the quarter and increased 10.8 percent on an organic basis, led by strong sales of Influvac®.

 

5

 

 

 

Medical Devices

($ in millions)

 

               % Change vs. 4Q19 
   Sales 4Q20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   1,369    1,888    3,257    (2.5)   4.9    1.7    (2.5)   1.2    (0.4)
Rhythm Management   248    284    532    (6.8)   2.1    (2.3)   (6.8)   (1.7)   (4.2)
Electrophysiology   184    266    450    (4.5)   0.1    (1.9)   (4.5)   (3.6)   (4.0)
Heart Failure   136    53    189    (6.7)   0.4    (4.8)   (6.7)   (2.3)   (5.5)
Vascular   225    378    603    (14.0)   (16.6)   (15.6)   (14.0)   (19.0)   (17.1)
Structural Heart   154    199    353    (9.1)   (3.3)   (5.9)   (9.1)   (7.0)   (7.9)
Neuromodulation   172    41    213    (1.6)   (12.7)   (4.0)   (1.6)   (15.7)   (4.6)
Diabetes Care   250    667    917    29.3    34.1    32.7    29.3    29.1    29.2 
                                              
Vascular Product Lines:                                             
Coronary and Endovasculara)   210    377    587    (12.3)   (16.4)   (15.0)   (12.3)   (18.8)   (16.5)

 

a)Includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products.

 

               % Change vs. 12M19 
   Sales 12M20   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   4,931    6,856    11,787    (8.2)   (0.1)   (3.7)   (8.2)   (0.3)   (3.8)
Rhythm Management   903    1,011    1,914    (14.5)   (7.1)   (10.7)   (14.5)   (7.2)   (10.8)
Electrophysiology   660    918    1,578    (11.0)   (6.2)   (8.3)   (11.0)   (6.8)   (8.6)
Heart Failure   547    193    740    (4.7)   (1.3)   (3.9)   (4.7)   (1.3)   (3.9)
Vascular   853    1,486    2,339    (18.6)   (17.6)   (18.0)   (18.6)   (17.4)   (17.8)
Structural Heart   540    707    1,247    (12.2)   (9.9)   (10.9)   (12.2)   (10.3)   (11.2)
Neuromodulation   564    138    702    (14.6)   (19.2)   (15.5)   (14.6)   (19.0)   (15.5)
Diabetes Care   864    2,403    3,267    27.4    30.2    29.5    27.4    30.1    29.4 
                                              
Vascular Product Lines:                                             
Coronary and Endovasculara)   785    1,478    2,263    (17.1)   (17.5)   (17.4)   (17.1)   (17.3)   (17.3)

 

a)Includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products.

 

Worldwide Medical Devices sales increased 1.7 percent on a reported basis in the fourth quarter and decreased 0.4 percent on an organic basis. Strong growth in Diabetes Care, led by FreeStyle Libre, was offset by reduced cardiovascular and neuromodulation procedure volumes due to the COVID-19 pandemic and lower Vascular sales in China, as a result of a new national tender program in that country. Excluding Vascular sales in China, global Vascular sales decreased 10.4 percent on an organic basis, and Medical Devices sales increased 1.4 percent on an organic basis in the fourth quarter.

 

In Diabetes Care, strong growth in the quarter was led by FreeStyle Libre, which grew 41.3 percent on a reported basis and 37.1 percent on an organic basis. For the full year, FreeStyle Libre grew 43.1 percent on a reported basis and 42.6 percent on an organic basis.

 

6

 

 

Abbott continues to strengthen its Medical Devices portfolio, with several key product approvals in 2020, including:

·U.S. FDA clearance of FreeStyle Libre 2 as an integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes, achieving the highest level of accuracy and performance standards.4
·CE Mark of FreeStyle Libre 3, which automatically delivers up-to-the-minute glucose readings, unsurpassed 14-day accuracy5 and real-time glucose alarms in the world's smallest and thinnest6 wearable glucose sensor.
·CE Mark of Libre Sense Glucose Sport Biosensor, a small wearable sensor that helps athletes better understand the efficacy of their nutritional choices on training and athletic performance.
·CE Mark of MitraClip G4, Abbott's next-generation MitraClip heart system, the leading minimally invasive mitral heart valve repair device in the world.
·CE Mark of TriClip, the world's first minimally invasive, clip-based device for repair of a leaky tricuspid heart valve.
·CE Mark of Tendyne, a first-of-its-kind technology to replace a faulty mitral heart valve.
·U.S. approval of Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, which include Bluetooth technology and a new patient smartphone app for improved remote monitoring and enhanced patient-physician engagement to help manage heart rhythm disorders.
·CE Mark of EnSite X EP System, a next-generation 3D cardiac mapping platform used for ablation therapy to treat abnormal heart rhythms.
·U.S. FDA clearance and CE Mark of the IonicRF™ Generator, a non-surgical, minimally invasive device that uses heat to target specific nerves for the management of chronic pain.

 

7

 

 

Abbott ISSUES guidance for 2021

Abbott projects full-year 2021 diluted earnings per share from continuing operations under GAAP of at least $3.74. Abbott forecasts specified items for the full-year 2021 of $1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $5.00 for full-year 2021.

 

Abbott declares 388th consecutive QUARTERLY DIVIDEND

On Dec. 11, 2020, the board of directors of Abbott increased the company's quarterly dividend to $0.45 per share from $0.36 per share, an increase of 25 percent. Abbott's cash dividend is payable Feb. 16, 2021, to shareholders of record at the close of business on Jan. 15, 2021.

 

Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

 

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

 

Abbott will live webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.

 

8

 

 

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2019 and in Item 1A, "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

 

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

 

Abbott Media:

Darcy Ross, 224-667-3655

Kate Dyer, 224-668-9965

  
 

 

1Fourth-quarter 2020 diluted EPS from continuing operations on a GAAP basis reflects 103.4 percent growth.

2Full year 2020 diluted EPS from continuing operations on a GAAP basis exceeded the guidance range Abbott issued in January 2020 of $2.35 to $2.45.

3Full year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of at least 50 percent versus the prior year.

4Based on FDA iCGM special controls.

5Alva Shridhara, Timothy Bailey, Ronald Brazg, Erwin S. Budiman, Kristin Castorino, Mark P. Christiansen, Gregory Forlenza, Mark Kipnes, David R. Liljenquist, and Hanqing Liu. "Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes." Journal of Diabetes Science and Technology, (September 2020). https://doi.org/10.1177/1932296820958754.

6Among patient-applied sensors. Data on File, Abbott Diabetes Care.

 

9

 

 

 

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Fourth Quarter Ended December 31, 2020 and 2019

(in millions, except per share data)

(unaudited)

 

    4Q20   4Q19  % Change  
Net Sales  $10,701   $8,314   28.7  
                
Cost of products sold, excluding amortization expense   4,493    3,434   30.8  
Amortization of intangible assets   508    483   5.2  
Research and development   698    595   17.5  
Selling, general, and administrative   2,570    2,413   6.5  
Total Operating Cost and Expenses   8,269    6,925   19.4  
                
Operating Earnings   2,432    1,389   75.0  
                
Interest expense, net   127    139   (8.3)  
Net foreign exchange (gain) loss   (5)   (2)  n/m  
Debt extinguishment costs   --    63   n/m  
Other (income) expense, net   (78)   (51)  49.6  
Earnings from Continuing Operations before taxes   2,388    1,240   92.4  
                
Tax expense on Earnings from Continuing Operations   230    191   20.2 1)
Earnings from Continuing Operations   2,158    1,049   105.5  
                
Earnings from Discontinued Operations, net of taxes   4    --   n/m  
                
Net Earnings  $2,162   $1,049   105.9  
                
Earnings from Continuing Operations, excluding               
Specified Items, as described below  $2,612   $1,705   53.2 2)
                
Diluted Earnings per Common Share from:               
Continuing Operations  $1.20   $0.59   103.4  
Discontinued Operations   --    --   n/m  
Total  $1.20   $0.59   103.4  
                
Diluted Earnings per Common Share from Continuing               
Operations, excluding Specified Items, as described below  $1.45   $0.95   52.6 2)
                
Average Number of Common Shares Outstanding               
Plus Dilutive Common Stock Options   1,789    1,781      

 

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

 

10

 

 

 

1)2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $10 million in excess tax benefits associated with share-based compensation.

 

2)2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $454 million, or $0.25 per share, for intangible amortization and impairment expenses and other net expenses primarily associated with acquisitions and restructuring actions.

 

2019 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $656 million, or $0.36 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

 

11

 

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Year Ended December 31, 2020 and 2019

(in millions, except per share data)

(unaudited)

 

    12M20    12M19   % Change  
Net Sales  $34,608   $31,904   8.5  
                
Cost of products sold, excluding amortization expense   15,003    13,231   13.4  
Amortization of intangible assets   2,132    1,936   10.1  
Research and development   2,420    2,440   (0.8) 1)
Selling, general, and administrative   9,696    9,765   (0.7)  
Total Operating Cost and Expenses   29,251    27,372   6.9  
                
Operating Earnings   5,357    4,532   18.2  
                
Interest expense, net   500    576   (13.2)  
Net foreign exchange (gain) loss   (8)   7   n/m  
Debt extinguishment costs   --    63   n/m  
Other (income) expense, net   (103)   (191)  (46.5)  
Earnings from Continuing Operations before taxes   4,968    4,077   21.8  
                
Tax expense on Earnings from Continuing Operations   497    390   27.3 2)
Earnings from Continuing Operations   4,471    3,687   21.2  
                
Earnings from Discontinued Operations, net of taxes   24    --   n/m  
                
Net Earnings  $4,495   $3,687   21.9  
                
Earnings from Continuing Operations, excluding               
Specified Items, as described below  $6,552   $5,810   12.8 3)
                
Diluted Earnings per Common Share from:               
Continuing Operations  $2.49   $2.06   20.9  
Discontinued Operations   0.01    --   n/m  
Total  $2.50   $2.06   21.4  
                
Diluted Earnings per Common Share from Continuing               
Operations, excluding Specified Items, as described below  $3.65   $3.24   12.7 3)
                
Average Number of Common Shares Outstanding               
Plus Dilutive Common Stock Options   1,786    1,781      

 

NOTES:

See tables on page 15 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

 

12

 

 

 

1)In 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired an R&D asset valued at $102 million, which was immediately expensed.

 

2)2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $170 million of tax benefits related to the impairment of certain assets, approximately $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $100 million in excess tax benefits associated with share-based compensation.

 

2019 Tax expense on Earnings from Continuing Operations includes the impact of a $86 million reduction of the transition tax associated with the Tax Cuts and Jobs Act (TCJA) and approximately $100 million in excess tax benefits associated with share-based compensation.

 

3)2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.081 billion, or $1.16 per share, for intangible amortization expense, impairment charges and other net expense primarily associated with acquisitions, restructuring actions and income from a litigation settlement.

 

2019 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.123 billion, or $1.18 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions.

 

13

 

 

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Fourth Quarter Ended December 31, 2020 and 2019

(in millions, except per share data)

(unaudited)

 

   4Q20 
    As
Reported
(GAAP) 		    Specified
Items		    As
Adjusted		    % to
Sales		 
Intangible Amortization  $508   $(508)  $--      
Gross Margin   5,700    557    6,257    58.5%
R&D   698    (61)   637    6.0%
SG&A   2,570    (56)   2,514    23.5%
Other (income) expense, net   (78)   23    (55)     
Earnings from Continuing Operations before taxes   2,388    651    3,039      
Tax expense on Earnings from Continuing Operations   230    197    427      
Earnings from Continuing Operations   2,158    454    2,612      
Diluted Earnings per Share from Continuing Operations  $1.20   $0.25   $1.45      

 

Specified items reflect intangible amortization expense of $508 million and other net expenses of $143 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 17 for additional details regarding specified items.

 

    4Q19 
    As
Reported
(GAAP)		    Specified
Items		    As
Adjusted		    % to
Sales		 
Intangible Amortization  $483   $(483)  $--      
Gross Margin   4,397    545    4,942    59.4%
R&D   595    (39)   556    6.7%
SG&A   2,413    (62)   2,351    28.3%
Debt extinguishment costs   63    (63)   --      
Other (income) expense, net   (51)   (5)   (56)     
Earnings from Continuing Operations before taxes   1,240    714    1,954      
Tax expense on Earnings from Continuing Operations   191    58    249      
Earnings from Continuing Operations   1,049    656    1,705      
Diluted Earnings per Share from Continuing Operations  $0.59   $0.36   $0.95      

 

Specified items reflect intangible amortization expense of $483 million and other expenses of $231 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 18 for additional details regarding specified items.

 

14

 

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Year Ended December 31, 2020 and 2019

(in millions, except per share data)

(unaudited)

 

    12M20 
    As
Reported
(GAAP) 		    Specified
Items		    As
Adjusted		    % to
Sales		 
Intangible Amortization  $2,132   $(2,132)  $--      
Gross Margin   17,473    2,452    19,925    57.6%
R&D   2,420    (125)   2,295    6.6%
SG&A   9,696    (75)   9,621    27.8%
Other (income) expense, net   (103)   (88)   (191)     
Earnings from Continuing Operations before taxes   4,968    2,740    7,708      
Tax expense on Earnings from Continuing Operations   497    659    1,156      
Earnings from Continuing Operations   4,471    2,081    6,552      
Diluted Earnings per Share from Continuing Operations  $2.49   $1.16   $3.65      

 

Specified items reflect intangible amortization expense of $2.132 billion and other net expenses of $608 million, primarily associated with acquisitions, restructuring actions, asset impairments, other expenses and litigation settlement income. See page 19 for additional details regarding specified items.

 

    12M19 
    As
Reported
(GAAP)		    Specified
Items		    As
Adjusted		    % to
Sales		 
Intangible Amortization  $1,936   $(1,936)  $--      
Gross Margin   16,737    2,140    18,877    59.2%
R&D   2,440    (198)   2,242    7.0%
SG&A   9,765    (240)   9,525    29.9%
Debt extinguishment costs   63    (63)   --      
Other (income) expense, net   (191)   (37)   (228)     
Earnings from Continuing Operations before taxes   4,077    2,678    6,755      
Tax expense on Earnings from Continuing Operations   390    555    945      
Earnings from Continuing Operations   3,687    2,123    5,810      
Diluted Earnings per Share from Continuing Operations  $2.06   $1.18   $3.24      

 

Specified items reflect intangible amortization expense of $1.936 billion and other expenses of $742 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 20 for additional details regarding specified items.

 

15

 

 

A reconciliation of the fourth-quarter tax rates for continuing operations for 2020 and 2019 is shown below:

 

    4Q20      
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		    Tax
Rate		      
As reported (GAAP)  $2,388   $230    9.6%   1)
Specified items   651    197           
Excluding specified items  $3,039   $427    14.1%     

 

    4Q19      
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		    Tax
Rate		      
As reported (GAAP)  $1,240   $191    15.4%     
Specified items   714    58           
Excluding specified items  $1,954   $249    12.8%     

 

1)2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $10 million in excess tax benefits associated with share-based compensation.

 

A reconciliation of the year-to-date tax rates for continuing operations for 2020 and 2019 is shown below:

 

    12M20      
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		    Tax
Rate		      
As reported (GAAP)  $4,968   $497    10.0%   2)
Specified items   2,740    659           
Excluding specified items  $7,708   $1,156    15.0%     

 

    12M19      
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		    Tax
Rate		      
As reported (GAAP)  $4,077   $390    9.6%   3)
Specified items   2,678    555           
Excluding specified items  $6,755   $945    14.0%     

 

2)2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $170 million of tax benefits related to the impairment of certain assets, approximately $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $100 million in excess tax benefits associated with share-based compensation.

 

3)Reported tax rate on a GAAP basis for 2019 includes the impact of a $86 million reduction of the transition tax associated with the TCJA and approximately $100 million in excess tax benefits associated with share-based compensation.

 

16

 

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2020

(in millions, except per share data)

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $23   $23   $508   $3   $557 
R&D   (2)   6    --    (65)   (61)
SG&A   (25)   (4)   --    (27)   (56)
Other (income) expense, net   24    --    --    (1)   23 
Earnings from Continuing Operations before taxes  $26   $21   $508   $96    651 
Tax expense on Earnings from Continuing Operations (d)                       197 
Earnings from Continuing Operations                      $454 
Diluted Earnings per Share from Continuing Operations                      $0.25 

 

The table above provides additional details regarding the specified items described on page 14.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention and the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)Other primarily relates to the impairment of an intangible asset and the net costs related to certain litigation.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

17

 

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2019

(in millions, except per share data)

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $34   $28   $483   $--   $545 
R&D   (15)   (22)   --    (2)   (39)
SG&A   (39)   (23)   --    --    (62)
Debt extinguishment costs   --    --    --    (63)   (63)
Other (income) expense, net   (5)   --    --    --    (5)
Earnings from Continuing Operations before taxes  $93   $73   $483   $65    714 
Tax expense on Earnings from Continuing Operations (d)                       58 
Earnings from Continuing Operations                      $656 
Diluted Earnings per Share from Continuing Operations                      $0.36 

 

The table above provides additional details regarding the specified items described on page 14.

 

a)Acquisition-related expenses include costs for tax and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, asset impairments, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)Other primarily relates to costs associated with the early extinguishment of debt.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

18

 

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Year Ended December 31, 2020

(in millions, except per share data)

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $84   $80   $2,132   $156   $2,452 
R&D   (10)   (3)   --    (112)   (125)
SG&A   (108)   (40)   --    73    (75)
Other (income) expense, net   21    --    --    (109)   (88)
Earnings from Continuing Operations before taxes  $181   $123   $2,132   $304    2,740 
Tax expense on Earnings from Continuing Operations (d)                      659 
Earnings from Continuing Operations                      $2,081 
Diluted Earnings per Share from Continuing Operations                      $1.16 

 

The table above provides additional details regarding the specified items described on page 15.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)Other primarily relates to impairment charges related to certain assets and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.

 

d)Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.

 

19

 

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Year Ended December 31, 2019

(in millions, except per share data)

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructure
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $103   $101   $1,936   $--   $2,140 
R&D   (38)   (44)   --    (116)   (198)
SG&A   (153)   (70)   --    (17)   (240)
Debt extinguishment costs   --    --    --    (63)   (63)
Other (income) expense, net   (15)   --    --    (22)   (37)
Earnings from Continuing Operations before taxes  $309   $215   $1,936   $218    2,678 
Tax expense on Earnings from Continuing Operations (d)                       555 
Earnings from Continuing Operations                      $2,123 
Diluted Earnings per Share from Continuing Operations                      $1.18 

 

The table above provides additional details regarding the specified items described on page 15.

 

a)Acquisition-related expenses include costs for tax and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities, and fair value adjustments to contingent consideration related to a business acquisition.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, asset impairments, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)Other primarily relates to the acquisition of R&D assets, costs associated with the early extinguishment of debt, charges related to the impairment of certain assets, and expenses related to certain litigation settlements.

 

d)Reflects the net tax benefit associated with the specified items, a reduction in the transition tax associated with the TCJA and excess tax benefits associated with share-based compensation.

 

###

 

20

 

 

 GRAPHIC 3 tm214153d1_ex99-1img001.jpg GRAPHIC begin 644 tm214153d1_ex99-1img001.jpg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end EX-101.SCH 4 abt-20210127.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 abt-20210127_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 abt-20210127_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] CHICAGO STOCK EXCHANGE, INC [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 abt-20210127_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 tm214153d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000001800 2021-01-27 2021-01-27 0000001800 us-gaap:CommonStockMember exch:XCHI 2021-01-27 2021-01-27 0000001800 us-gaap:CommonStockMember exch:XNYS 2021-01-27 2021-01-27 iso4217:USD shares iso4217:USD shares 0000001800 false Common Shares, Without Par Value ABT 8-K 2021-01-27 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value ABT NYSE CHX false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Jan. 27, 2021
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 27, 2021
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Central Index Key 0000001800
Entity Tax Identification Number 36-0698440
Entity Incorporation, State or Country Code IL
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 3 96 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm214153d1_8k.htm abt-20210127.xsd abt-20210127_def.xml abt-20210127_lab.xml abt-20210127_pre.xml tm214153d1_ex99-1.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/exch/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm214153d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20210127_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm214153d1_8k.htm" ] }, "labelLink": { "local": [ "abt-20210127_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "abt-20210127_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "abt-20210127.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 3, "nsprefix": "abt", "nsuri": "http://abbott.com/20210127", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm214153d1_8k.htm", "contextRef": "From2021-01-27to2021-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm214153d1_8k.htm", "contextRef": "From2021-01-27to2021-01-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001104659-21-007942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-007942-xbrl.zip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�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�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end